Notice of NIST's Consortium for the Advancement of Genome Editing, 1335-1336 [2018-00315]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 8 / Thursday, January 11, 2018 / Notices
for the revised certifications provided at
the end of the Final Rule.9 Commerce
intends to reject factual submissions in
any proceeding segments if the
submitting party does not comply with
applicable revised certification
requirements.
srobinson on DSK9F5VC42PROD with NOTICES
Extension of Time Limits Regulation
Parties may request an extension of
time limits before a time limit
established under Part 351 expires, or as
otherwise specified by the Secretary.
See 19 CFR 351.302. In general, an
extension request will be considered
untimely if it is filed after the time limit
established under Part 351 expires. For
submissions which are due from
multiple parties simultaneously, an
extension request will be considered
untimely if it is filed after 10:00 a.m. on
the due date. Examples include, but are
not limited to: (1) Case and rebuttal
briefs, filed pursuant to 19 CFR 351.309;
(2) factual information to value factors
under 19 CFR 351.408(c), or to measure
the adequacy of remuneration under 19
CFR 351.511(a)(2), filed pursuant to 19
CFR 351.301(c)(3) and rebuttal,
clarification and correction filed
pursuant to 19 CFR 351.301(c)(3)(iv); (3)
comments concerning the selection of a
surrogate country and surrogate values
and rebuttal; (4) comments concerning
U.S. Customs and Border Protection
data; and (5) quantity and value
questionnaires. Under certain
circumstances, Commerce may elect to
specify a different time limit by which
extension requests will be considered
untimely for submissions which are due
from multiple parties simultaneously. In
such a case, Commerce will inform
parties in the letter or memorandum
setting forth the deadline (including a
specified time) by which extension
requests must be filed to be considered
timely. This modification also requires
that an extension request must be made
in a separate, stand-alone submission,
and clarifies the circumstances under
which Commerce will grant untimelyfiled requests for the extension of time
limits. These modifications are effective
for all segments initiated on or after
October 21, 2013. Please review the
final rule, available at https://
www.gpo.gov/fdsys/pkg/FR-2013-09-20/
html/2013-22853.htm, prior to
submitting factual information in these
segments.
9 See Certification of Factual Information To
Import Administration During Antidumping and
Countervailing Duty Proceedings, 78 FR 42678 (July
17, 2013) (Final Rule); see also the frequently asked
questions regarding the Final Rule, available at
https://enforcement.trade.gov/tlei/notices/factual_
info_final_rule_FAQ_07172013.pdf.
VerDate Sep<11>2014
00:05 Jan 11, 2018
Jkt 244001
These initiations and this notice are
in accordance with section 751(a) of the
Act (19 U.S.C. 1675(a)) and 19 CFR
351.221(c)(1)(i).
Dated: January 8, 2018.
James Maeder,
Senior Director performing the duties of
Deputy Assistant Secretary for Antidumping
and Countervailing Duty Operations.
[FR Doc. 2018–00356 Filed 1–10–18; 8:45 am]
BILLING CODE 3510–DS–P
DEPARTMENT OF COMMERCE
National Institute of Standards and
Technology
Notice of NIST’s Consortium for the
Advancement of Genome Editing
National Institute of Standards
and Technology.
ACTION: Notice of Research Consortium.
AGENCY:
The National Institute of
Standards and Technology (NIST), an
agency of the United States Department
of Commerce is establishing the Genome
Editing Consortium with the goal of
bringing together stakeholders across
the genome editing community to
identify and address measurement and
standards needs to support this
technical area. The Consortium intends
to evaluate genome editing assay
pipelines, develop benchmark materials,
generate benchmark data, develop
suggested minimal information
reporting for public studies, and
generate a common lexicon for genome
editing studies, with the intent these
resources can be used to increase
confidence in evaluating genome editing
and lower the risk to utilizing these
technologies in research and
commercial products. Participation fees
will be at least $20,000 annually or inkind contributions of equivalent value.
Participants will be required to sign a
Cooperative Research and Development
Agreement (CRADA).
DATES: NIST will accept letters of
interest containing required information
for participation in this Consortium
until January 1, 2020. Acceptance of
participants into the Consortium after
the Commencement Date will depend
on eligibility as determined by NIST
based upon the information provided in
the letter of interest and upon the
availability resources.
ADDRESSES: Information in response to
this notice, including completed letters
of interest or requests for additional
information about the Consortium can
be directed via mail to the Consortium
Manager, Dr. Samantha Maragh,
Biosystems and Biomaterials Division of
SUMMARY:
PO 00000
Frm 00009
Fmt 4703
Sfmt 4703
1335
NIST’s Material Measurement
Laboratory, 100 Bureau Drive, Mail Stop
8312, Gaithersburg, Maryland 20899, or
via electronic mail to samantha@
nist.gov, or by telephone at (301) 975–
4947.
FOR FURTHER INFORMATION CONTACT: For
further information about participation
opportunities to join the Genome
Editing Consortium, please contact
Jeffrey DiVietro, CRADA Officer,
National Institute of Standards and
Technology’s Technology Partnerships
Office, by mail to 100 Bureau Drive,
Mail Stop 2200, Gaithersburg, Maryland
20899, by electronic mail to
jeffrey.divietro@nist.gov, or by
telephone at (301) 975–8779.
SUPPLEMENTARY INFORMATION: Targeted
Genome Editing is a technology space
where there is a great need for reliable
measurement methods for assuring the
results of editing. Modalities for targeted
genome editing include but are not
limited to Zinc Finger Proteins (ZFPs),
Homing Endonucleases, Transcription
Activator-Like Nucleases (TALENs) and
Clustered, Regularly Interspaced
Palindromic Repeats (CRISPR). These
technologies are being actively pursued
by industry, academic, government and
non-profit sectors to advance medicine
and bioscience in areas such as:
Regenerative medicine, synthetic
biology, novel antimicrobials and
antivirals, protein therapeutic
biomanufacturing, agriculture and
global food production. Utilizing these
technologies for production and
medicine will first require robust
quantitative assays and measurements
to enable high confidence
characterization of DNA alterations
resulting from genome editing.
NIST has reached out to companies to
assess their measurement needs, and
has co-led workshops that have brought
together experts across the genome
editing field including stakeholders in
industry, academia and government.
These discussions have identified
common pre-competitive measurement
needs that if resolved can push forward
the field as it relates to understanding
the reliability of data from assays being
used to measuring aspects of genome
edited cells.
This Consortium’s purpose is to
develop measurement solutions and
standards to advance confidence in
measurements supporting the genome
editing technology space.
The Consortium will have three
working groups with the following
responsibilities:
(1) Specificity Measurements:
a. Design, generate, and evaluate a set
of purified DNA samples and mixtures
E:\FR\FM\11JAN1.SGM
11JAN1
srobinson on DSK9F5VC42PROD with NOTICES
1336
Federal Register / Vol. 83, No. 8 / Thursday, January 11, 2018 / Notices
that can be used to mimic both of ontarget and off-target genome editing
induced variants at known frequencies
in a background of human genomic
DNA which can be used to benchmark
validation of sequencing pipelines
intended to identify genome editing
induced variants.
b. Design and conduct controlled
evaluations of assays intended to
identify where genome editing enzymes
have been active in a genome, with an
experimental design that allows for
enough power to assess the sources of
variability, repeatability, and
reproducibility within an assay.
(2) Data and Meta Data:
a. Identify community norms for data
formats and tools for benchmarking data
analysis including in silico data sets and
an experimental data set.
b. Determine the type of meta data
that would be needed to be shared,
housed, and interrogated from genome
editing experiments.
(3) Lexicon: Identify terms and related
definitions to form a common genome
editing community lexicon.
No proprietary information will be
shared as part of the Consortium.
Process: Interested parties with
relevant genome editing associated
capabilities (see below), products, and/
or technical expertise to support this
Consortium should contact NIST using
the information provided in the
ADDRESSES section of this notice. NIST
will then provide each interested party
with a letter of interest template, which
the party must complete, and submit to
NIST. NIST will contact interested
parties if there are questions regarding
the responsiveness of the letters. NIST
will select participants who have
submitted complete letters of interest
based on the capabilities listed below.
Eligibility will be determined solely by
NIST based on information provided by
interested organizations and upon the
availability of necessary resources to
NIST.
To participate, the eligible applicant
will be required to sign a CRADA with
NIST.
Requirements: Each letter of interest
should provide the following
information:
(1) A description of the experience in
genome editing or genome engineering,
bioinformatics, next-generation
sequencing, detection or quantitation of
DNA variants or related expertise to
contribute to the Consortium.
(2) Subgroups or topic areas of
interest for participation. There is no
limit on the number of areas of
participation.
(3) List of interested party’s
anticipated participants.
VerDate Sep<11>2014
00:05 Jan 11, 2018
Jkt 244001
Letters of interest may not include
business proprietary information. NIST
will not treat any information provided
in response to this Notice as proprietary
information. NIST will notify each
organization of its eligibility. In order to
participate in this Consortium, each
eligible organization must sign a
CRADA for this Consortium. All
participants to this Consortium will be
bound by the same terms and
conditions. Participants will be required
to contribute financial or equivalent inkind resources, as determined by NIST,
of at least $20,000. NIST does not
guarantee participation in the
Consortium or in any other
collaboration to any organization
submitting a Letter of Interest.
Kevin Kimball,
NIST Chief of Staff.
[FR Doc. 2018–00315 Filed 1–10–18; 8:45 am]
BILLING CODE 3510–13–P
DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric
Administration
RIN 0648–XF917
Fisheries of the South Atlantic; South
Atlantic Fishery Management Council;
Public Meetings
National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
ACTION: Notice of meeting of the South
Atlantic Fishery Management Council’s
Citizen Science Advisory Panel
Projects/Topics Management; Finance &
Infrastructure; Volunteers;
Communication/Outreach/Education;
and Data Management Action Teams.
AGENCY:
The South Atlantic Fishery
Management Council (Council) will
hold an all-hands meeting of its Citizen
Science Advisory Panel Projects/Topics
Management; Finance & Infrastructure;
Volunteers; Communication/Outreach/
Education; and Data Management
Action Teams via webinar.
DATES: The Projects/Topics
Management; Finance & Infrastructure;
Volunteers; Communication/Outreach/
Education; and Data Management
Action Team meeting will be held on
Wednesday, January 31, 2018 at 9 a.m.
The meeting is scheduled to last
approximately three hours. Additional
Action Team webinar dates and times
will publish in a subsequent issue in the
Federal Register.
ADDRESSES:
PO 00000
Frm 00010
Fmt 4703
Sfmt 9990
FOR FURTHER INFORMATION CONTACT:
Amber Von Harten, Citizen Science
Program Manager, SAFMC; phone (843)
302–8433 or toll free (866) SAFMC–10;
fax: (843) 769–4520; email:
amber.vonharten@safmc.net.
The
Council created a Citizen Science
Advisory Panel Pool in June 2017. The
Council appointed members of the
Citizen Science Advisory Panel Pool to
five Action Teams in the areas of
Volunteers, Data Management, Projects/
Topics Management, Finance, and
Communication/Outreach/Education to
develop program policies and
operations for the Council’s Citizen
Science Program.
Each Action Team has been meeting
since August 2017 to work on
developing recommendations on
program policies and operations to be
reviewed by the Council’s Citizen
Science Committee. The January 31,
2018 meeting will bring all members of
all five Action Teams together to review
and discuss draft recommendations
from each Action Team. Public
comment will be accepted at the
beginning of the meeting.
Items to be addressed during these
meetings:
SUPPLEMENTARY INFORMATION:
Authority: 15 U.S.C. 3710a.
SUMMARY:
Meeting address: The meeting will be
held via webinar and is open to
members of the public. Webinar
registration is required and registration
links will be posted to the Citizen
Science program page of the Council’s
website at www.safmc.net.
Council address: South Atlantic
Fishery Management Council, 4055
Faber Place Drive, Suite 201, N
Charleston, SC 29405.
1. Overview and discussion of Action
Team draft recommendations
2. Other Business
Special Accommodations
These meetings are physically
accessible to people with disabilities.
Requests for auxiliary aids should be
directed to the council office (see
ADDRESSES) 3 days prior to the meeting.
Note: The times and sequence specified in
this agenda are subject to change.
Authority: 16 U.S.C. 1801 et seq.
Dated: January 8, 2018.
Tracey L. Thompson,
Acting Deputy Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2018–00372 Filed 1–10–18; 8:45 am]
BILLING CODE 3510–22–P
E:\FR\FM\11JAN1.SGM
11JAN1
]]>Agencies
[Federal Register Volume 83, Number 8 (Thursday, January 11, 2018)]
[Notices]
[Pages 1335-1336]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-00315]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
National Institute of Standards and Technology
Notice of NIST's Consortium for the Advancement of Genome Editing
AGENCY: National Institute of Standards and Technology.
ACTION: Notice of Research Consortium.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Standards and Technology (NIST), an
agency of the United States Department of Commerce is establishing the
Genome Editing Consortium with the goal of bringing together
stakeholders across the genome editing community to identify and
address measurement and standards needs to support this technical area.
The Consortium intends to evaluate genome editing assay pipelines,
develop benchmark materials, generate benchmark data, develop suggested
minimal information reporting for public studies, and generate a common
lexicon for genome editing studies, with the intent these resources can
be used to increase confidence in evaluating genome editing and lower
the risk to utilizing these technologies in research and commercial
products. Participation fees will be at least $20,000 annually or in-
kind contributions of equivalent value. Participants will be required
to sign a Cooperative Research and Development Agreement (CRADA).
DATES: NIST will accept letters of interest containing required
information for participation in this Consortium until January 1, 2020.
Acceptance of participants into the Consortium after the Commencement
Date will depend on eligibility as determined by NIST based upon the
information provided in the letter of interest and upon the
availability resources.
ADDRESSES: Information in response to this notice, including completed
letters of interest or requests for additional information about the
Consortium can be directed via mail to the Consortium Manager, Dr.
Samantha Maragh, Biosystems and Biomaterials Division of NIST's
Material Measurement Laboratory, 100 Bureau Drive, Mail Stop 8312,
Gaithersburg, Maryland 20899, or via electronic mail to
[email protected], or by telephone at (301) 975-4947.
FOR FURTHER INFORMATION CONTACT: For further information about
participation opportunities to join the Genome Editing Consortium,
please contact Jeffrey DiVietro, CRADA Officer, National Institute of
Standards and Technology's Technology Partnerships Office, by mail to
100 Bureau Drive, Mail Stop 2200, Gaithersburg, Maryland 20899, by
electronic mail to [email protected], or by telephone at (301)
975-8779.
SUPPLEMENTARY INFORMATION: Targeted Genome Editing is a technology
space where there is a great need for reliable measurement methods for
assuring the results of editing. Modalities for targeted genome editing
include but are not limited to Zinc Finger Proteins (ZFPs), Homing
Endonucleases, Transcription Activator-Like Nucleases (TALENs) and
Clustered, Regularly Interspaced Palindromic Repeats (CRISPR). These
technologies are being actively pursued by industry, academic,
government and non-profit sectors to advance medicine and bioscience in
areas such as: Regenerative medicine, synthetic biology, novel
antimicrobials and antivirals, protein therapeutic biomanufacturing,
agriculture and global food production. Utilizing these technologies
for production and medicine will first require robust quantitative
assays and measurements to enable high confidence characterization of
DNA alterations resulting from genome editing.
NIST has reached out to companies to assess their measurement
needs, and has co-led workshops that have brought together experts
across the genome editing field including stakeholders in industry,
academia and government. These discussions have identified common pre-
competitive measurement needs that if resolved can push forward the
field as it relates to understanding the reliability of data from
assays being used to measuring aspects of genome edited cells.
This Consortium's purpose is to develop measurement solutions and
standards to advance confidence in measurements supporting the genome
editing technology space.
The Consortium will have three working groups with the following
responsibilities:
(1) Specificity Measurements:
a. Design, generate, and evaluate a set of purified DNA samples and
mixtures
[[Page 1336]]
that can be used to mimic both of on-target and off-target genome
editing induced variants at known frequencies in a background of human
genomic DNA which can be used to benchmark validation of sequencing
pipelines intended to identify genome editing induced variants.
b. Design and conduct controlled evaluations of assays intended to
identify where genome editing enzymes have been active in a genome,
with an experimental design that allows for enough power to assess the
sources of variability, repeatability, and reproducibility within an
assay.
(2) Data and Meta Data:
a. Identify community norms for data formats and tools for
benchmarking data analysis including in silico data sets and an
experimental data set.
b. Determine the type of meta data that would be needed to be
shared, housed, and interrogated from genome editing experiments.
(3) Lexicon: Identify terms and related definitions to form a
common genome editing community lexicon.
No proprietary information will be shared as part of the
Consortium.
Process: Interested parties with relevant genome editing associated
capabilities (see below), products, and/or technical expertise to
support this Consortium should contact NIST using the information
provided in the ADDRESSES section of this notice. NIST will then
provide each interested party with a letter of interest template, which
the party must complete, and submit to NIST. NIST will contact
interested parties if there are questions regarding the responsiveness
of the letters. NIST will select participants who have submitted
complete letters of interest based on the capabilities listed below.
Eligibility will be determined solely by NIST based on information
provided by interested organizations and upon the availability of
necessary resources to NIST.
To participate, the eligible applicant will be required to sign a
CRADA with NIST.
Requirements: Each letter of interest should provide the following
information:
(1) A description of the experience in genome editing or genome
engineering, bioinformatics, next-generation sequencing, detection or
quantitation of DNA variants or related expertise to contribute to the
Consortium.
(2) Subgroups or topic areas of interest for participation. There
is no limit on the number of areas of participation.
(3) List of interested party's anticipated participants.
Letters of interest may not include business proprietary
information. NIST will not treat any information provided in response
to this Notice as proprietary information. NIST will notify each
organization of its eligibility. In order to participate in this
Consortium, each eligible organization must sign a CRADA for this
Consortium. All participants to this Consortium will be bound by the
same terms and conditions. Participants will be required to contribute
financial or equivalent in-kind resources, as determined by NIST, of at
least $20,000. NIST does not guarantee participation in the Consortium
or in any other collaboration to any organization submitting a Letter
of Interest.
Authority: 15 U.S.C. 3710a.
Kevin Kimball,
NIST Chief of Staff.
[FR Doc. 2018-00315 Filed 1-10-18; 8:45 am]
BILLING CODE 3510-13-P
